Replies to post #233298 on NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

NWBO is priced like this is the only chess move left and I'm fine with those odds. But is LL fooling herself into believing that the results shes seeing are due to dcvax? I say this with sincerity. Perhaps the patients would've rebooted their immune response after SOC anyway. 5 ALA would provide that chance to a natural recovery the same way it opens the door for dcvax. It also becomes easier to fool yourself when the benefit is seen in the mgmt methylated patients, which could be why she always has a frog in her throat when describing brads histology and mgmt +. I get the vibe that she knows people can make that argument against her but still feels dcvax is at work.

The delta between GTR and partial resection might make it arguable that recurrence isn't as big a barrier as we think, if dcvax is actually having an effect, which would lend itself back to crossover issues.

I'm still okay with these odds.

[sharpie510]

because I personally do believe DCVax-L does not typically help much after recurrence without surgery combined with DCVax-L. We know that only three such combinations occurred as of the March 2017 data. Anything after that would have been on patients in the trial with much later recurrence.

That is a great point as to why the late vaccination patients may not do as well. They had to take the vaccine made with the original gbm tumor, and not DCVax-L made with their new recurrent tumor. I think the compassionate cases outside of the trial that were recurrent gbm seemingly did well because they got DCVax-L made with their latest resected tumor. So, while in the trial, DCVax-L may not help much for the soc crossover patients after recurrence, outside the restrictions of the trial, recurrent gbm patients would likely be helped because their DCVax-L will be made with the latest tumor and treatment would not be delayed.